A 32-year-old woman with generalized tonic-clonic seizures has been on phenytoin for 3 years. She now presents with progressive cognitive slowing, ataxia, and nystagmus. Which is the most common cause of these chronic neurological symptoms in this clinical context?

Explanation

## Chronic Phenytoin Neurotoxicity ### Clinical Presentation The triad of **cognitive slowing, ataxia, and nystagmus** in a patient on long-term phenytoin is pathognomonic for chronic dose-related phenytoin toxicity. **Key Point:** Chronic phenytoin neurotoxicity is the most common cause of progressive neurological decline in patients on long-term phenytoin therapy. It is a predictable, dose-dependent effect that improves with dose reduction or drug discontinuation. ### Mechanism of Chronic Phenytoin Neurotoxicity 1. **Cerebellar dysfunction** → ataxia, dysarthria, nystagmus 2. **Cerebral cortical effects** → cognitive slowing, memory impairment, personality changes 3. **Peripheral neuropathy** → distal sensory loss, weakness 4. **Dose-dependent:** Occurs when serum levels exceed therapeutic range (10–20 μg/mL) or with chronic accumulation ### Chronic Neurological Manifestations of Phenytoin | Manifestation | Mechanism | Reversibility | | --- | --- | --- | | Nystagmus | Cerebellar | Reversible | | Ataxia | Cerebellar | Reversible | | Cognitive slowing | Cerebral cortical | Reversible | | Tremor | Cerebellar/extrapyramidal | Reversible | | Peripheral neuropathy | Axonal degeneration | Partially reversible | | Coarsening of features | Connective tissue | Partially reversible | | Hirsutism | Androgen-like effect | Reversible | ### Distinguishing Features from Alternatives ```mermaid flowchart TD A[Patient on phenytoin with cognitive slowing, ataxia, nystagmus]:::outcome --> B{Serum phenytoin level?}:::decision B -->|Elevated or high-normal| C[Chronic phenytoin toxicity]:::action B -->|Therapeutic| D[Check liver function]:::decision D -->|Normal| E[Consider other causes]:::outcome D -->|Abnormal| F[Hepatic encephalopathy]:::urgent A --> G{Duration of symptoms?}:::decision G -->|Acute onset| H[Acute intoxication]:::urgent G -->|Insidious over months/years| I[Chronic toxicity]:::action ``` **High-Yield:** The key distinguishing feature is the **chronic, insidious onset** over months to years in a patient with stable seizure control. Acute toxicity presents suddenly with ataxia, nystagmus, and confusion. **Clinical Pearl:** Chronic phenytoin toxicity is often mistaken for seizure-related cognitive decline or underlying progressive neurological disease. Always measure serum phenytoin levels and consider dose reduction as the first intervention. ### Management 1. **Measure serum phenytoin level** (therapeutic: 10–20 μg/mL) 2. **Reduce dose** if level is elevated or high-normal 3. **Monitor for symptom improvement** (usually within 2–4 weeks) 4. **Consider switching to alternative antiepileptic** (levetiracetam, lamotrigine, valproate) if symptoms persist or recur **Warning:** Do NOT abruptly discontinue phenytoin — risk of seizure recurrence. Taper gradually over 2–4 weeks. [cite:Harrison 21e Ch 369]